Published: Feb. 24, 2023
Compared to the history of NAFLD briefly summarized above, notions that and NAFLD-related metabolic conditions could also be a risk factor for development primary liver cancer (PLC) in limited proportion individuals are more recent (Table 1) [8-13].While it is logical somewhat foreseeable PLC may eventually develop some with NAFLD, observations substantiate probably unexpected theory that, further PLCs,
Language: Английский
Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(6), P. 1524 - 1541
Published: Sept. 18, 2023
While the links between metabolic dysfunction associated steatotic liver disease (MASLD) and obesity, insulin resistance are widely appreciated, there a host of complex interactions other endocrine axes. it can be difficult to definitively distinguish direct causal relationships those attributable increased adipocyte mass, is substantial evidence indirect specific dysregulation severity MASLD. Strong effects exists for low levels growth hormone, sex hormones, thyroid hormone with development disease. The impact steroid e.g. cortisol dehydropepiandrosterone, adipokines much more divergent. Thoughtful assessment, based on individual risk factors findings, also management non-insulin axes should performed in evaluation Multiple therapeutic pharmaceutical targets have emerged that leverage various reduce fibroinflammatory cascade steatohepatitis (MASH).
Language: Английский
Citations
86
Journal of Hazardous Materials, Journal Year: 2024, Volume and Issue: 468, P. 133835 - 133835
Published: Feb. 19, 2024
Language: Английский
Citations
37
Archives of Medical Research, Journal Year: 2024, Volume and Issue: 55(6), P. 103043 - 103043
Published: Aug. 1, 2024
Language: Английский
Citations
35
Internal and Emergency Medicine, Journal Year: 2023, Volume and Issue: 18(4), P. 993 - 1006
Published: Feb. 17, 2023
Abstract The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic disease. NAFLD points to excessive hepatic fat storage and no evidence secondary accumulation in patients with “no or little alcohol consumption”. Both etiology pathogenesis are largely unknown, a definitive therapy is lacking. Since very often closely associated metabolic dysfunctions, consensus process ongoing shift acronym MAFLD, i.e., metabolic-associated change terminology likely improve classification affected individuals, awareness, comprehension pathophysiological aspects involved, choice more personalized therapeutic approaches while avoiding intrinsic stigmatization due “non-alcoholic”. Even recently, other sub-classifications have been proposed concentrate heterogeneous causes under one umbrella. While awaiting additional validation studies this field, we discuss main reasons underlying important paradigm.
Language: Английский
Citations
26
Metabolites, Journal Year: 2024, Volume and Issue: 14(1), P. 40 - 40
Published: Jan. 8, 2024
This narrative review aims to illustrate the notion that nonalcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated (MASH), is a systemic disorder featuring both adverse hepatic and extrahepatic outcomes. In recent years, several NASH trials have failed identify effective pharmacological treatments and, therefore, lifestyle changes are cornerstone of therapy for NASH. with this context, we analyze epidemiological burden possible pathogenetic factors involved. These include genetic factors, insulin resistance, lipotoxicity, immuno-thrombosis, oxidative stress, reprogramming metabolism, hypoxia, all which eventually culminate in low-grade chronic inflammation increased risk fibrosis progression. The explanations underlying failure also accurately examined. We conclude high heterogeneity NASH, resulting from variable backgrounds, exposure, responses different stresses, susceptibility hepatocyte differences repair-response, calls personalized medicine approaches involving research on noninvasive biomarkers. Future should aim at achieving complete assessment determinants, modifiers, correlates thus adopting more holistic unbiased approach, notably including cardiovascular–kidney–metabolic outcomes, without restricting therapeutic perspectives histological surrogates liver-related outcomes alone.
Language: Английский
Citations
13
Liver International, Journal Year: 2024, Volume and Issue: 44(7), P. 1513 - 1525
Published: April 3, 2024
Abstract Background Recent observational studies examining the association between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease (MASLD) have reported conflicting results. We performed a meta‐analysis to quantify magnitude H. MASLD. Methods systematically searched three large electronic databases identify eligible (published up 30 November 2023) in which biopsy, imaging methods or blood‐based biomarkers/scores were used for diagnosing Data from selected extracted, was using common random‐effects modelling. Statistical heterogeneity among published studies, subgroup analyses, meta‐regression analyses publication bias assessed. Results A total 28 (24 cross‐sectional 4 longitudinal studies) identified, including 231 291 middle‐aged individuals predominantly Asian ethnicity (~95%). Meta‐analysis showed that significantly associated with small increase prevalent MASLD ( n = 24 studies; odds ratio 1.11, 95% CI 1.05–1.18; I 2 63%). data an increased developing incident over mean 5‐year follow‐up 1.20, 95%CI 1.08–1.33; 44%). Sensitivity did not modify these The funnel plot reveal any significant bias. Conclusions is mildly Further well‐designed prospective mechanistic are required better decipher complex link
Language: Английский
Citations
9
Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(2)
Published: April 7, 2024
Chronic kidney disease (CKD) and nonalcoholic fatty liver (NAFLD), metabolic dysfunction-associated (MAFLD) steatotic (MASLD) account for substantial financial burden worldwide. These alarming features call enhanced efforts to prevent manage the development progression of CKD. Accumulating evidence supporting a causal role NAFLD/MAFLD/MASLD-in CKD opens new horizons achieve this aim. Recent epidemiological studies meta-analyses exploring association NAFLD/MAFLD/MASLD with characteristics associated odds incident are discussed. The involved pathomechanisms, including common soil hypothesis, genetics, gut dysbiosis, portal hypertension, examined in detail. Finally, lifestyle changes (diet physical exercise), direct manipulation microbiota, drug approaches involving statins, renin-angiotensin-aldosterone system inhibitors, GLP-1 Receptor Agonists, Sodium-glucose cotransporter-2, pemafibrate, vonafexor within context prevention management among those NAFLD/MAFLD/MASLD. evolving nomenclature may generate confusion practicing clinicians investigators. However, comparative investigating pros contra different nomenclatures identify most useful definitions strategies identify, prevent, halt onset
Language: Английский
Citations
9
Liver International, Journal Year: 2024, Volume and Issue: 44(3), P. 848 - 864
Published: Jan. 23, 2024
Abstract Background and Aims Thyroid axis is currently under investigation as a therapeutic target in metabolic dysfunction‐associated steatotic liver disease (MASLD). function was examined herein the full spectrum of disease. Methods Subjects were recruited had biopsies two Gastroenterology‐Hepatology Clinics (Greece Australia) one Bariatric‐Metabolic Surgery Clinic (Italy). The main working sample n = 677 subjects with MASLD after excluding abnormal free thyroxine levels. Participants classified according to thyroid‐stimulating hormone (TSH) standard criteria: Subclinical hyperthyroidism (<0.4 uIU/mL); Euthyroidism relatively low (0.4 <2.5 euthyroidism high (2.5–4.0 subclinical hypothyroidism (>4 uIU/mL). Results TSH continuous variable positively associated significant fibrosis ( F ≥ 2), steatohepatitis (MASH) at‐risk MASH. 2 (odds ratio [OR] 3.47, 95% confident interval [CI] [1.50, 8.05], p .02), MASH (OR 3.44, CI [1.48, 7.98] .001) 3.88, [1.76, 8.55], .001), before controlling for adiposity, central obesity, insulin resistance. When leptin, adiponectin, or growth differentiation factor‐15 moderators, significance lost. Sex‐specific analysis revealed strong association between presence among women, eliminated only when adipokines/mitokines adjusted for. Restricted cubic spline associations outcomes ‐values < .01) inflection points being 2.49, 2.67 6.96. Conclusions These observations provide support studies on administration thyroid therapeutics liver‐specific receptor agonists across continuum.
Language: Английский
Citations
7
Liver International, Journal Year: 2024, Volume and Issue: 44(5), P. 1129 - 1141
Published: March 1, 2024
Abstract Background Metabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) a biomarker advanced fibrosis in MAFLD and PRO‐C3 may be involved renal fibrosis. We aimed to use measurements generate new algorithmic score test the prediction with (MAFLD–CKD). Methods A derivation independent validation cohort 750 129 Asian patients biopsy‐confirmed were included. Serum concentration was measured regression analyses performed examine associations MAFLD–CKD. derivative algorithm MAFLD–CKD evaluated receiver operator characteristic (ROC) curve analysis. Results The study included two cohorts ( n = 180 MAFLD–CKD; mean‐eGFR: 94.93 mL/min/1.73 m 2 ; median‐urinary albumin‐to‐creatinine ratio: 6.58 mg/mmol). associated severity MAFLD‐CKD independently (adjusted odds ratio 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). non‐invasive (termed PERIOD) including efficiently predicted (AUROC .842, CI: .805–.875). Accuracy, specificity negative predictive values 80.2%, 85.1% 88.4%, respectively. In cohort, PERIOD had good diagnostic performance .807, .691–.893) similar results all patient subgroups. subgroup, accuracy identifying further improved by combining PRO‐C3‐based ADAPT Agile 3+ scores .90, .836–.964). Conclusions helpful accurately predicting can also used assess people
Language: Английский
Citations
5
Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(3)
Published: June 26, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum cardio-nephro-metabolic and vascular manifestations inherent in highlights complex profile CVD associated with this condition. However, current approaches to assessing lack specificity, predominantly relying on traditional markers. Although it widely accepted that patients advanced fibrosis are more prone risk, recent evidence suggests isolated focus may overlook remarkable phenotypic variability across entire population. Emerging data indicate a progressive escalation parallel severity MASLD, highlighting need precise staging inform accurate assessment. To address challenge, we propose novel sequential approach assessment MASLD. While factors remain essential, incorporating liver-specific parameters enhances stratification guides targeted interventions mitigate substantial burden vulnerable This involves initial screening using FIB-4 NAFLD score, followed by imaging-based non-invasive techniques individuals at intermediate-high fat quantification low-risk individuals. Future prospective investigations should simultaneous use biomarkers imaging modalities evaluate, sex-specific manner, efficacy proposed determine optimal thresholds steatosis
Language: Английский
Citations
5